Cardiology overview congenital heart disease: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
==Mitochondrial Cardiomyopathy== | ==Mitochondrial Cardiomyopathy== | ||
* Mitochondrial cardiomyopathy is associated with an increase in the pCO2 due to a reduction in ventilation. | * Mitochondrial cardiomyopathy is associated with an increase in the pCO2 due to a reduction in ventilation. | ||
==Patent Foramen Ovale (PFO)== | |||
=== Treatment=== | |||
* In the PFO patient who has had their first [[cryptogenic stroke]], the treatment of choice as aspirin. | |||
* The benefit of PFO closure is not well established | |||
* The benefit of [[Coumadin]] in the patient with PFO is not well established, and this therapy should be reserved for those patients with [[atrial fibrillation]] or [[venous thromboembolism]]. | |||
==References== | ==References== | ||
Revision as of 17:43, 31 October 2011
|
Cardiology Overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Coarctaion
- May be associated with bicuspid aortic stenosis
- Imaging follow-up is recommended to look for aneurysm formation.
Mitochondrial Cardiomyopathy
- Mitochondrial cardiomyopathy is associated with an increase in the pCO2 due to a reduction in ventilation.
Patent Foramen Ovale (PFO)
Treatment
- In the PFO patient who has had their first cryptogenic stroke, the treatment of choice as aspirin.
- The benefit of PFO closure is not well established
- The benefit of Coumadin in the patient with PFO is not well established, and this therapy should be reserved for those patients with atrial fibrillation or venous thromboembolism.